Dr. Reddy’s Laboratories, an integrated global pharmaceutical company committed to providing affordable and innovative medicines for healthier lives, has launched Paricalcitol Capsules, 1 mcg, 2 mcg and 4 mcg, a therapeutic equivalent generic version of Zemplar (Paricalcitol) Capsules in the US market on June 24, 2014, following the approval by the United States Food & Drug Administration (US FDA).

The Zemplar brand and generic had US sales of approximately $109.6 million MAT for the most recent twelve months ending in March 2014 according to IMS Health.

Dr. Reddy’s Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg are available in bottle counts of 30.